<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Business &amp; Industry</title>
	<atom:link href="https://www.worldpharmatoday.com/business-industry/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.worldpharmatoday.com</link>
	<description>Magazine for the C-level Pharma Executives</description>
	<lastBuildDate>Tue, 21 Apr 2026 13:39:53 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.worldpharmatoday.com/wp-content/uploads/2025/12/cropped-World-Pharma-Today-fevicon-32x32.jpg</url>
	<title>Business &amp; Industry</title>
	<link>https://www.worldpharmatoday.com</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Boehringer Ingelheim Launches New AI R&#038;D Centre in London</title>
		<link>https://www.worldpharmatoday.com/news/boehringer-ingelheim-launches-new-ai-rd-centre-in-london/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 21 Apr 2026 13:39:53 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Techno Trends]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/boehringer-ingelheim-launches-new-ai-rd-centre-in-london/</guid>

					<description><![CDATA[<p>Boehringer Ingelheim has introduced a new artificial intelligence (AI) and machine learning (ML) facility in London, strengthening its efforts to integrate advanced technologies into pharmaceutical research. The AI R&#38;D centre will focus on applying AI models to support the discovery and development of targeted medicines, particularly for patients with unmet medical needs. Located in King’s [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/boehringer-ingelheim-launches-new-ai-rd-centre-in-london/">Boehringer Ingelheim Launches New AI R&D Centre in London</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks</title>
		<link>https://www.worldpharmatoday.com/news/eli-lilly-kelonia-acquisition-advances-in-2b-deal-talks/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Tue, 21 Apr 2026 05:47:56 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Acquisition]]></category>
		<category><![CDATA[Eli Lilly]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/eli-lilly-kelonia-acquisition-advances-in-2b-deal-talks/</guid>

					<description><![CDATA[<p>Eli Lilly and Company is in advanced discussions to acquire Kelonia Therapeutics for more than $2 billion, according to a report by The Wall Street Journal. The report, citing people familiar with the matter, indicates that a deal could be finalized as early as Monday and may include additional payments tied to the achievement of [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/eli-lilly-kelonia-acquisition-advances-in-2b-deal-talks/">Eli Lilly Kelonia Acquisition Advances in $2B Deal Talks</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>FDA Advisory Panel to Assess Oversight of Peptide Substances</title>
		<link>https://www.worldpharmatoday.com/news/fda-advisory-panel-to-assess-oversight-of-peptide-substances/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 17 Apr 2026 12:18:52 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[FDA]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/fda-advisory-panel-to-assess-oversight-of-peptide-substances/</guid>

					<description><![CDATA[<p>The U.S. Food and Drug Administration is preparing to revisit its stance on a group of peptide substances, as its Pharmacy Compounding Advisory Committee schedules a summer meeting that could influence how these products are regulated. The FDA advisory panel is set to evaluate whether certain peptides currently restricted from compounding use should be reconsidered, [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/fda-advisory-panel-to-assess-oversight-of-peptide-substances/">FDA Advisory Panel to Assess Oversight of Peptide Substances</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>PacBio, Covaris Advance HiFi Sequencing Workflow for FFPE</title>
		<link>https://www.worldpharmatoday.com/news/pacbio-covaris-advance-hifi-sequencing-workflow-for-ffpe/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Fri, 17 Apr 2026 06:09:06 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/pacbio-covaris-advance-hifi-sequencing-workflow-for-ffpe/</guid>

					<description><![CDATA[<p>A new integrated approach to long-read sequencing of archived tissue samples has been introduced through a collaboration between PacBio and Covaris, with the workflow set to be presented at the American Association for Cancer Research Annual Meeting. The jointly developed solution combines Covaris’ extraction capabilities with PacBio’s sequencing technologies to enable a seamless transition from [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/pacbio-covaris-advance-hifi-sequencing-workflow-for-ffpe/">PacBio, Covaris Advance HiFi Sequencing Workflow for FFPE</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Lilly Acquires CrossBridge to Expand Next-Gen ADC Pipeline</title>
		<link>https://www.worldpharmatoday.com/news/lilly-acquires-crossbridge-to-expand-next-gen-adc-pipeline/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 16 Apr 2026 10:09:30 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/lilly-acquires-crossbridge-to-expand-next-gen-adc-pipeline/</guid>

					<description><![CDATA[<p>Eli Lilly and Company has entered into an agreement to acquire all outstanding shares of CrossBridge Bio in a transaction valued at up to $300m, structured through an upfront payment and additional milestone-based compensation linked to development progress. The deal centres on strengthening Lilly’s oncology pipeline, with a particular focus on advancing next-generation antibody-drug conjugates [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/lilly-acquires-crossbridge-to-expand-next-gen-adc-pipeline/">Lilly Acquires CrossBridge to Expand Next-Gen ADC Pipeline</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>AbbVie Secures $745M Haisco Deal to Expand Pain Drug Pipeline</title>
		<link>https://www.worldpharmatoday.com/news/abbvie-secures-745m-haisco-deal-to-expand-pain-drug-pipeline/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 16 Apr 2026 10:05:22 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/abbvie-secures-745m-haisco-deal-to-expand-pain-drug-pipeline/</guid>

					<description><![CDATA[<p>AbbVie has entered into a global licensing agreement with China-based Haisco Pharmaceutical valued at up to $715 million, aiming to strengthen its presence in pain therapeutics. The Haisco deal grants AbbVie exclusive rights to develop, manufacture, and commercialize multiple investigational compounds worldwide, excluding mainland China, Hong Kong, and Macau. These assets, spanning preclinical through Phase [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/abbvie-secures-745m-haisco-deal-to-expand-pain-drug-pipeline/">AbbVie Secures $745M Haisco Deal to Expand Pain Drug Pipeline</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Aragen ChemiSHE Lab Launch Strengthens Women in Pharma R&#038;D</title>
		<link>https://www.worldpharmatoday.com/news/aragen-chemishe-lab-launch-strengthens-women-in-pharma-rd/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Thu, 16 Apr 2026 06:05:30 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/aragen-chemishe-lab-launch-strengthens-women-in-pharma-rd/</guid>

					<description><![CDATA[<p>Aragen has introduced ChemiSHE, positioning it as India’s first chemistry synthesis laboratory fully operated and led by women scientists. The facility was inaugurated on 8 April 2026 at the company’s Mallapur campus in Hyderabad, marking a targeted step by the global Contract Research, Development, and Manufacturing Organization (CRDMO) to advance gender diversity within its scientific [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/aragen-chemishe-lab-launch-strengthens-women-in-pharma-rd/">Aragen ChemiSHE Lab Launch Strengthens Women in Pharma R&D</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Novo Nordisk OpenAI Partnership Accelerates Drug Development</title>
		<link>https://www.worldpharmatoday.com/news/novo-nordisk-openai-partnership-accelerates-drug-development/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 15 Apr 2026 12:24:16 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[Drug Research]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/novo-nordisk-openai-partnership-accelerates-drug-development/</guid>

					<description><![CDATA[<p>Danish pharmaceutical major Novo Nordisk has entered into a strategic collaboration with OpenAI to embed artificial intelligence across its drug development operations, with the stated goal of accelerating the delivery of new treatments. Announced on Tuesday, the initiative is designed to strengthen the company’s ability to identify and advance therapies more efficiently, particularly in areas [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/novo-nordisk-openai-partnership-accelerates-drug-development/">Novo Nordisk OpenAI Partnership Accelerates Drug Development</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Regeneron Telix Radiopharma Deal Targets Cancer Therapies</title>
		<link>https://www.worldpharmatoday.com/news/regeneron-telix-radiopharma-deal-targets-cancer-therapies/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Wed, 15 Apr 2026 05:04:32 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/regeneron-telix-radiopharma-deal-targets-cancer-therapies/</guid>

					<description><![CDATA[<p>Regeneron Pharmaceuticals has entered into a strategic agreement with Telix Pharmaceuticals to jointly develop next-generation oncology treatments, in a deal valued at up to $2.1 billion in milestone payments. The radiopharma collaboration will combine Regeneron’s antibody-based discovery capabilities with Telix’s isotope delivery platforms, targeting multiple solid tumor indications. Both companies will equally share development costs [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/regeneron-telix-radiopharma-deal-targets-cancer-therapies/">Regeneron Telix Radiopharma Deal Targets Cancer Therapies</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
		<item>
		<title>Drug Manufacturing Deals Shift to Europe Despite Tariffs</title>
		<link>https://www.worldpharmatoday.com/news/drug-manufacturing-deals-shift-to-europe-despite-tariffs/</link>
		
		<dc:creator><![CDATA[Yuvraj]]></dc:creator>
		<pubDate>Sat, 11 Apr 2026 08:39:47 +0000</pubDate>
				<category><![CDATA[Business & Industry]]></category>
		<category><![CDATA[News]]></category>
		<category><![CDATA[Production & Manufacturing]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<guid isPermaLink="false">https://www.worldpharmatoday.com/uncategorized/drug-manufacturing-deals-shift-to-europe-despite-tariffs/</guid>

					<description><![CDATA[<p>Biopharma companies are continuing to redirect production strategies toward Europe, even as U.S. policymakers attempt to strengthen domestic output through tariffs and onshoring measures. According to GlobalData, the latest data highlights a clear divergence in deal activity, with drug manufacturing deals increasingly favoring European markets over the United States. The shift underscores how companies are [&#8230;]</p>
The post <a href="https://www.worldpharmatoday.com/news/drug-manufacturing-deals-shift-to-europe-despite-tariffs/">Drug Manufacturing Deals Shift to Europe Despite Tariffs</a> first appeared on <a href="https://www.worldpharmatoday.com">World Pharma Today</a>.]]></description>
		
		
		
			</item>
	</channel>
</rss>
